U.S. Mulls Ban on Chinese Optical Modules; Lumentum and Coherent to Benefit in the Medium Term
nashnova research
Wedbush Securities analyst Matt Bryson says a U.S. ban on Chinese optical transceivers would hand Lumentum and Coherent mid-term share gains and near-term pricing power — but Chinese suppliers hold roughly two-thirds of the global market, and the ban is far from certain.
Who is making this call, and what is the bottom line?
Wedbush Securities analyst Matt Bryson published a note on the proposed U.S. ban on Chinese optical transceivers.
Core thesis: if the ban takes effect, Lumentum (LITE) and Coherent (COHR) are the primary beneficiaries.
The upside has two layers — mid-term market-share gains and near-term pricing power on advanced transceivers.
This means → once supply is artificially narrowed, the makers still standing get to set higher prices.
How dominant are Chinese suppliers, and why is the ban hard to push through?
Chinese suppliers currently hold roughly two-thirds of the global optical-transceiver market, led by Innolight and Eoptolink.
In plain terms = out of every three transceivers shipped worldwide, about two come from China — cutting them off leaves an enormous gap.
U.S. suppliers lack the capacity to fully replace that volume; Bryson warns the ban "would create supply issues for U.S. data-center operators."
Microsoft, Amazon, and Google have all spoken out against the ban — buyer resistance is the biggest obstacle to implementation.
Which other companies are caught in the crossfire?
Bryson notes that gallium-arsenide substrate supplier AXT (AXTI) and wafer foundry Tower Semiconductor (TSEM) face limited near-to-mid-term impact.
Over the longer term, however, the ban could disrupt their product roadmaps and weigh on earnings expectations.
This means → these two are neither clear winners nor clear losers — the risk sits further out on the timeline.
Where does the ban stand now, and what should investors watch?
The ban has not yet taken effect; whether it lands — and on what timetable — remains unknown.
This means → the window and magnitude of any benefit for Lumentum and Coherent hinge entirely on policy progress.
In plain terms = the analyst has drawn an "if … then …" roadmap, but the "if" at the starting line has not materialized.
市场有风险,内容仅供研究参考,不构成投资建议。
